30
Participants
Start Date
December 8, 2021
Primary Completion Date
November 10, 2023
Study Completion Date
June 13, 2024
Trilaciclib
Single-use, sterile powder to be reconstituted and further diluted with 250 milliliters (mL) of normal saline (sodium chloride solution 0.9%) or dextrose 5% in water (D5W)
Sacituzumab Govitecan-hziy
10 milligram per kilogram (mg/kg) reconstituted to a concentration of 1.1 mg/mL to 3.4 mg/mL in normal saline
Inova Schar Cancer Institute, Fairfax
Virginia Oncology Associates, Norfolk
Oncology and Hematology Associates of Southwest Virginia, Inc, Roanoke
Orlando Health Cancer Institute, Orlando
Memorial Healthcare System, Hollywood
Minnesota Oncology Hematology, P.A., Woodbury
Duly Health and Care, Joliet
Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas
Texas Oncology - Longview Cancer Center, Longview
Texas Oncology - Austin Central, Austin
Rocky Mountain Cancer Centers, Denver
Ironwood Physicians, Chandler
Comprehensive Cancer Centers of Nevada, Las Vegas
Los Angeles Hematology Oncology Medical Group, Los Angeles
Valkyrie Clinical Trials, Los Angeles
UCLA Hematology/Oncology Parkside, Santa Monica
PIH Health, Whittier
Comprehensive Blood & Cancer Center, Bakersfield
Northwest Cancer Specialists, PC, Tigard
Multicare Health System, Auburn
Northwest Medical Specialties, PLLC, Tacoma
New England Cancer Specialists, Scarborough
Lead Sponsor
G1 Therapeutics, Inc.
INDUSTRY